Rating Change
Wells Fargo analysts reiterated a Equal-Weight rating on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on August 07, 2026.
reiterateNASDAQ:AMPH
Wells Fargo Reiterates Equal-Weight Rating on Amphastar Pharmaceuticals, Inc. (AMPH)
Rating Change Wells Fargo analysts reiterated a Equal-Weight rating on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) on August 07, 2026. Market Context Amphastar Pharmaceuticals,…
At a glance
Key takeaways
- Wells Fargo reiterated an Equal-Weight rating on Amphastar Pharmaceuticals (AMPH) on August 7, 2026, indicating neutral sentiment from the analyst.
- Among the 10 most recent analyst ratings, the consensus is mixed with 2 Buy ratings, 7 Hold ratings, and 1 Sell rating, reflecting divided opinion on the stock.
- AMPH trades at $20.90 with a market capitalization of $929.6 million and has declined 7.6% over the past 52 weeks.
- Recent analyst activity shows a shift toward caution, with Bank of America Securities downgrading to Underperform in late June 2026, while most other analysts maintain neutral positions.
Market Context
Amphastar Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $20.90 with a market capitalization of $929.6M. The stock has declined 7.6% over the past 52 weeks.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Amphastar Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Amphastar Pharmaceuticals, Inc.
Among the 10 most recent ratings: 2 Buy, 7 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 07, 2026 | Wells Fargo | Equal-Weight | N/A |
| Jun 29, 2026 | B of A Securities | Underperform | N/A |
| Jun 03, 2026 | Barclays | Equal-Weight | N/A |
| May 14, 2026 | Wells Fargo | Equal-Weight | N/A |
| May 11, 2026 | Piper Sandler | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View AMPH Stock Page
Frequently Asked Questions
What does a Equal-Weight rating mean for AMPH?
A Equal-Weight rating from Wells Fargo reflects the analyst's outlook on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AMPH forecast page.